Drug Therapy of Systemic Lupus Erythematosus
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 73
Special Issue Editor
Special Issue Information
Dear Colleagues,
The landscape of SLE therapy has experienced significant progress following decades of setbacks and challenges, with the approvals of belimumab, anifrolumab, and voclosporin. More importantly, phase II trials have yielded promising results for TYK2 inhibitor deucravacitinib for general SLE and B-cell depletion therapy with obinutuzumab for lupus nephritis, potentially heralding successful phase III trials. Innovative cell therapies, particularly CD19 targeted CAR T-cell therapy, have demonstrated remarkable preliminary efficacy in SLE patients, paving the way for phase II/III trials. This evidence indicates a rapidly evolving field, with the potential to significantly alter SLE management and improve patient outcomes.
This Special Issue will comprehensively summarize the progress in SLE drug therapy over the past decade and explore emerging treatments. We seek submissions of original research, reviews, and clinical trial reports that delve into these advancements. To this end, contributions will highlight new pharmacological agents, cellular therapies, and personalized medicine approaches that are shaping the future of SLE treatment.
Dr. Dionysis Nikolopoulos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- systemic lupus erythematosus
- treatment
- drugs
- tailored strategies
- precision medicine
- biologics
- cell therapy
- randomized clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
